Please login to the form below
Bayer veteran joins Aurinia as CEO
Stephen Zaruby spent 20 years at German pharma company
Aurinia Pharmaceuticals has appointed Stepen Zaruby as president and CEO.
His career includes a 20-year stint at German company Bayer, including spells managing its domestic and international anti-infectives, quinolone and hospital/surgical business franchises.
Mmost recently he served as president at ZymoGenetics until its acquisition by Bristol-Myers Squibb in 2010. Since then he has worked as an independent consultant in life sciences.
Commenting on his latest appointment, Zaruby said he was looking forward to the future for kidney-focused Aurinia as it looks to launch its first drug.
“Aurinia is well positioned to bring voclosporin forward as an important new treatment for lupus nephritis,” he said.
Aurinia's chair Dr Richard Glickman said: “Stephen is a seasoned leader with a strong track record of delivering strategic direction and operational excellence to both established and emerging life sciences companies.
“He is exceptionally qualified to help us build our voclosporin franchise and sharpen our execution."
Subscribe to our email news alerts
- World AIDS Day 35: Medscape’s Commitment to the Elimination of HIV through Education and Looking Towards the Future
- No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards
- Building trust with HCPs: 6 takeaways from our industry webinar
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
No results were found
PMHub
Wiley
Wiley is a global leader in research and education. We clear the path for seekers of knowledge, leading the way...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
